Moss, 15 December 2022

Reference is made to the annual general meeting 18 May 2022 where a statement of remuneration to key personnel was given. In accordance with this statement the board of Gentian Diagnostics ASA has allocated a total of 219,996 options to key employees under the existing option program.

The following number of options have been allocated to primary insiders of Gentian Diagnostics ASA:

Hilja Ibert, Chief Executive Officer: 80,000 options. Following the allocations Ms. Ibert holds 6,525 shares and 359,924 options 

Njaal Kind, Group Chief Financial Officer: 19,996 options. Following the allocations Mr. Kind holds 21,125 shares and 175,666 options in the Company.

Torsten Knüttel, Vice President R&D: 10,000 options. Following the allocation Mr. Knüttel holds 1,125 shares and 40,000 options in the Company.

Jack Andreassen, Vice President Business Development:  10,000 options. Following the allocation Mr. Andreassen hold 4,385 shares and 32,500 options in the Company.

Markus Jaquemar, Vice President Sales and Marketing: 25,000 options. Following the allocation Mr. Jaquemar holds 47,500 options in the Company. 

The exercise price for the options granted is NOK 46,67 being the average volume-weighted share price on the Oslo Stock Exchange from 1 January 2022 to 13 December 2022. The right to exercise the options is vested over a period of 2 years, with 50% of the options vesting by the end of each year as follows: (i) 50% of the options granted, no earlier than 3 years after the allocation date (ii) 50% of the options granted, no earlier than 4 years after the allocation date. 

Attached are the notifications of the transactions pursuant to the market abuse regulation article 19. 

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact:

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525